Reshma Rangwala, MD, PhD
Chief Medical Officer & Head of Research
Dr. Rangwala is the Chief Medical Officer and Head of Research and Karyopharm. She oversees all aspects of research, from discovery and early development through regulatory approval. Dr. Rangwala brings more than a decade of experience in oncology and drug development to her role at Karyopharm. She was most recently the Chief Medical Officer at Aravive, where she led the clinical development of batiraxcept across multiple tumor types. Prior to Aravive, she served as Vice President, Medical, at Genmab where she led the clinical development program for a first-in-class antibody drug conjugate and managed clinical strategy, protocol development, data monitoring, data analysis, study report authoring, and biologic licensing application preparations. Prior to Genmab, she served as Executive Clinical Director at Merck & Co., where she was involved in the clinical development of KEYTRUDA in non-small cell lung cancer and gynecologic malignancies. Dr. Rangwala received her B.S. in Biology from Duke University and her M.D./Ph.D. from the University of Cincinnati College of Medicine. She completed her internal medicine residency at Barnes Jewish Hospital in St. Louis, MO and her medical oncology fellowship at the Hospital of the University of Pennsylvania.